Boston Scientific Corp. posted another eye-popping quarterly report, led by a 177% year-over-year increase in its electrophysiology business to $527 million, which exceeded consensus expectations by $99 million. That stunning EP growth follows 125% growth in the second quarter and 70% in the first quarter, all largely attributed to the Farapulse pulsed field ablation system, which achieved unprecedented adoption rates. Read More
In what seems a replay of concerns about technetium shortages from the 2010s, a bipartisan group of members of the U.S. House Energy & Commerce Committee has called for a study of the availability of medical isotopes for U.S. citizens. Read More
Cellbion Co. Ltd. debuted on the tech-heavy Kosdaq board of the Korea Exchange Oct. 16, with share prices closing upward at ₩20,650 (US$14.94) – outdoing its initial price of ₩15,000 per share for 1.9 million shares. Read More
The EU's regulatory crisis continues to roil relations between Brussels and stakeholders in the health care sector, and the European Parliament reacted with a message to the European Commission to revise the Medical Device Regulation. Read More
The Japanese government, industry and academia are deliberating health care policies and initiatives to boost Japan’s role in the future of regenerative medicine, experts at Bio Japan 2024 said, as the fruits of cell and gene therapy research come to fruition with new approvals. Read More
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allurion Technologies, Angiodynamics, Biosig Technologies, Guided Therapeutics, Quest Diagnostics, Rhine Pharma, Shifamed, Teal Health, Telix, Tioga. Read More
